Yenom23 thanks for the link! Also: Why would big pharma be interested in little Respiri? The opportunity to provide a critical asthma self-monitoring product/solution, and E-Health SaaS platform is most likely motivation enough for big players to tie up with Respiri. However there is an additional angle which may link Respiri to big pharma companies who are focused on the development of asthma Biologics – these include AstraZeneca, Novartis, GSK, a division of Roche called Genetech, and Sanofi.
There was an article via Asthma Australia in the last week highlighting that asthma biologics will be made more accessible to people with severe asthma via the PBS (pharmaceutical benefits scheme). A couple of items to note a) these drugs are expensive - $450-1500 per month b) big pharma is spending big dollars to continue the development of biologics and c) pharma will have ambitions of expanding their use and making them accessible to more patients than just the severe. (https://asthma.org.au/about-us/media/life-changing-biologics-therapies-made-more-accessible-to-people-with-severe-asthma/).
Respiri and Wheezo is very valuable where the patient use of Wheezo can provide the evidence of a need for biologics (ie existing medication plan not working) and Big pharma will also want as much patient data as possible to continue developing asthma biologics.
